Validation of the PHQ-9 depression scale in Ethiopian cancer patients attending the oncology clinic at Tikur Anbessa specialized hospital.

Journal: BMC psychiatry

Volume: 20

Issue: 1

Year of Publication: 2020

Affiliated Institutions:  Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. mikyas@gmail.com. Department of Pyschiatry, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia. Department of Neurology, College of Health Science, Addis Ababa University, Addis Ababa, Ethiopia.

Abstract summary 

Although depression is highly prevalent among cancer patients, it is often underdiagnosed and poorly managed particularly in developing nations. These shortcomings can have substantial adverse effects not only on the disease prognosis but also on patients' quality of life. The Patient Health Questionnaire-9 is a widely used depression screening tool but it has not been validated among patients with chronic illnesses such as cancer in Ethiopia. We aim to validate the PHQ-9 among Ethiopian cancer patients in an outpatient setting.A cross-sectional study was conducted among cancer patients attending the oncology clinic at Tikur Anbessa Specialized Hospital (TASH). We assessed criterion validity and performance of the PHQ-9 test against the gold standard Mini-International Neuropsychiatric Interview (MINI) diagnostic tool among patients with cancer. The MINI was administered by psychiatric nurses who were blind to the initial PHQ-9 screening tool.A total of 163 patients completed the 2 stages of a diagnostic interview in the study. The majority (64%) of the participants were women, the mean age was 46 (13.5) years. Using the gold standard MINI test the prevalence of Major Depressive Episode (MDE) was 15%. The internal consistency (Cronbach's α) for PHQ-9 was 0.78 suggesting good (acceptable) internal consistency for the reliability of the test scores. When the total PHQ-9 score was used to identify cases of MDE, the Area under the Curve (AUC) was 0.93 (95% confidence interval [CI], 0.88-0.97) on Receiver Operating Characteristic (ROC) analysis. This shows evidence for the excellent discriminating power of the PHQ-9 between cases and non-cases of MDE. At cutoff point ≥4, the PHQ-9 had a sensitivity of 88% and specificity of 78.1% on the ROC curve to detect MDE.PHQ-9 is a reliable and valid instrument to detect MDE among individuals with chronic conditions such as cancer patients in outpatient settings and it can be used in resource-limited settings for early diagnosis and proper therapy of such patients.

Authors & Co-authors:  Degefa Mikyas M Dubale Benyam B Bayouh Fikirte F Ayele Biniyam B Zewde Yared Y

Study Outcome 

Source Link: Visit source

Statistics
Citations :  World Health Organization, latest global cancer data Globocan Database, 2018, http://gco.iarc.fr/.
Authors :  5
Identifiers
Doi : 446
SSN : 1471-244X
Study Population
Male,Female
Mesh Terms
Cross-Sectional Studies
Other Terms
Cancer;Depression;Ethiopia;Patient Health Questionnaire-9 (PHQ-9);Validation
Study Design
Cross Sectional Study
Study Approach
Country of Study
Ethiopia
Publication Country
England